NO20001087L - Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer - Google Patents

Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer

Info

Publication number
NO20001087L
NO20001087L NO20001087A NO20001087A NO20001087L NO 20001087 L NO20001087 L NO 20001087L NO 20001087 A NO20001087 A NO 20001087A NO 20001087 A NO20001087 A NO 20001087A NO 20001087 L NO20001087 L NO 20001087L
Authority
NO
Norway
Prior art keywords
diseases
treatment
muscle
medication
extension
Prior art date
Application number
NO20001087A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001087D0 (no
Inventor
Ke Lignell
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20001087(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Publication of NO20001087L publication Critical patent/NO20001087L/no
Publication of NO20001087D0 publication Critical patent/NO20001087D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20001087A 1997-09-04 2000-03-02 Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer NO20001087D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
PCT/SE1998/001526 WO1999011251A1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases

Publications (2)

Publication Number Publication Date
NO20001087L true NO20001087L (no) 2000-03-02
NO20001087D0 NO20001087D0 (no) 2000-03-02

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001087A NO20001087D0 (no) 1997-09-04 2000-03-02 Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer

Country Status (13)

Country Link
US (1) US6245818B1 (sv)
EP (1) EP1011653B1 (sv)
JP (1) JP3660244B2 (sv)
AT (1) ATE230985T1 (sv)
AU (1) AU727349B2 (sv)
CA (1) CA2299366C (sv)
DE (1) DE69810784T2 (sv)
DK (1) DK1011653T3 (sv)
ES (1) ES2191329T3 (sv)
NO (1) NO20001087D0 (sv)
PL (1) PL338982A1 (sv)
SE (1) SE512531C2 (sv)
WO (1) WO1999011251A1 (sv)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
EP2392562B1 (en) 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
WO2004021798A1 (es) * 2002-09-03 2004-03-18 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
AU2004285394B2 (en) * 2003-11-03 2009-01-08 Astrazeneca Ab Imidazo (1,2-A) pyridine derivatives for the treatment of silent gastro-esophageal reflux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
EP1719506A4 (en) * 2004-02-04 2011-01-26 Fuji Chem Ind Co Ltd GENETIC EXPRESSION REGULATING AGENT
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060167319A1 (en) * 2004-10-01 2006-07-27 Lockwood Samuel F Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
WO2006105214A2 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) * 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) * 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) * 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
EP0806946A2 (de) * 1995-02-03 1997-11-19 Basf Aktiengesellschaft Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
DE69810784D1 (de) 2003-02-20
CA2299366C (en) 2008-04-22
DK1011653T3 (da) 2003-05-26
SE9703191L (sv) 1999-03-05
SE9703191D0 (sv) 1997-09-04
ATE230985T1 (de) 2003-02-15
CA2299366A1 (en) 1999-03-11
EP1011653B1 (en) 2003-01-15
DE69810784T2 (de) 2003-11-13
SE512531C2 (sv) 2000-03-27
EP1011653A1 (en) 2000-06-28
US6245818B1 (en) 2001-06-12
JP3660244B2 (ja) 2005-06-15
AU727349B2 (en) 2000-12-14
AU9098998A (en) 1999-03-22
JP2001514215A (ja) 2001-09-11
ES2191329T3 (es) 2003-09-01
PL338982A1 (en) 2000-12-04
WO1999011251A1 (en) 1999-03-11
NO20001087D0 (no) 2000-03-02

Similar Documents

Publication Publication Date Title
NO20001087D0 (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
IS4516A (is) Nýtt lyfjaform
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
BR9811086A (pt) Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
AR002724A1 (es) Peptido purificado fisiologicamente activo, sales de adicion de acido y sales de bases de dicho peptido, formas de dosificacion oral, intra-traqueal ynasal que comprenden a dicho peptido, formulacion farmaceutica que comprende a dicho peptido, usos de dicho peptido, metodo para la preparacion de dicha
WO1999018941A3 (en) Ih-MODULATORS
AU3401093A (en) Therapeutic agent for threatened abortion
EE9900346A (et) Viljatusevastane ja viljastumisvõimet tõstev ravim
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
HUP0104941A2 (hu) Több gyógyszerformát tartalmazó bliszter
RU97116821A (ru) Способ лечения респираторных заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application